2025 Q4 -tulosraportti
Vain PDF
39 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenCircio has a management with an unusually strong combination of circRNA expertise, pharma experience and transactional understanding. The management and primary insiders also have significant exposure through shares, options and warrants, and thus have economic alignment with the shareholders.- ·3 t sittenWhen should one enter Circio again at the latest? When are important days?
·55 min sittenAt the latest one day before a stock exchange announcement about an acquisition…. Your question is impossible to answer, especially if we don't know if you are a trader or are long in Circio. But right now, you at least have a golden opportunity to secure an option to buy the share at a specific price if you are considering entering now: If you buy warrants (last price Friday:kr 0.45) then you can, until June 9th, consider whether you wish to buy the share for kr 8.2508 REGARDLESS of what price the Circio share has. And should the price fall below kr 8.2508, you simply buy the share without exercising the warrants. Be aware that the price of warrants often rises more sharply than the share price now that the VWAP period is over. 
·7 t sittenI have read a lot about Circio and circRNA, but have never fully understood what AAV actually is and why it is relevant. For those of us who lack basic biotech knowledge, it can be useful to have things explained at an amateur level. I have no intention of filling the feed with AI content, but I thought this one might be interesting for several people. It was generated by Claude and I think it's worth sharing. What is AAV? AAV stands for adeno-associated virus. It is a small virus that occurs naturally in humans – most of us have had it without noticing anything at all. It doesn't make anyone sick and is therefore ideal as a transport vehicle for medicine. Researchers have practically emptied the virus of all genetic content and use the empty shell – called a capsid – as a biological package. Inside the package, they place a therapeutic gene, i.e., a corrected version of a gene that is defective in the patient. Think of it as a letter. AAV is the envelope. The gene is the letter inside. The cell is the recipient that opens the envelope and reads the instructions. What happens inside the cell? When AAV delivers the gene into the cell, the cell begins to read the instructions and produce the protein the gene codes for. If, for example, the patient lacks a specific protein that keeps the heart healthy, AAV can deliver the instruction that causes the heart to produce this protein itself. That is why AAV gene therapy is revolutionary – in theory, hereditary diseases can be cured with a single treatment. Problem 1 – Can only be used once: The body is smart. After the first time it sees the envelope – i.e., the AAV capsid – it produces antibodies against it. The next time you try to send a new letter in the same envelope, the immune system immediately attacks it before it arrives. You cannot re-dose the patient with the same AAV type. This is a critical problem because many diseases require sustained treatment over time, not just a single dose. Problem 2 – High doses and toxicity: For enough letters to reach the correct cells, an extremely large number of envelopes must be sent at once. Imagine sending a million letters for 10,000 to reach the correct address. The problem is that so many envelopes at once overwhelm the immune system. The body interprets it as a massive attack and reacts with strong inflammation – in the worst case, acute immune shock which can be fatal. Several patients have actually died in clinical studies because of this. Problem 3 – Liver off-targeting: AAV tends to end up in the liver regardless of where in the body it is actually addressed. If the letter is intended for the heart or the eye, many envelopes still end up in the liver – where they are not needed and can potentially cause damage. Problem 4 – Short duration: Even when the letter arrives and the cell reads the instructions, the effect is limited in time. Cells divide and dilute the content, and the protein produced decreases over time. One might get a few months to a few years of effect, but rarely lifelong treatment from a single dose.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
39 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenCircio has a management with an unusually strong combination of circRNA expertise, pharma experience and transactional understanding. The management and primary insiders also have significant exposure through shares, options and warrants, and thus have economic alignment with the shareholders.
- ·3 t sittenWhen should one enter Circio again at the latest? When are important days?·55 min sittenAt the latest one day before a stock exchange announcement about an acquisition…. Your question is impossible to answer, especially if we don't know if you are a trader or are long in Circio. But right now, you at least have a golden opportunity to secure an option to buy the share at a specific price if you are considering entering now: If you buy warrants (last price Friday:kr 0.45) then you can, until June 9th, consider whether you wish to buy the share for kr 8.2508 REGARDLESS of what price the Circio share has. And should the price fall below kr 8.2508, you simply buy the share without exercising the warrants. Be aware that the price of warrants often rises more sharply than the share price now that the VWAP period is over.
- ·7 t sittenI have read a lot about Circio and circRNA, but have never fully understood what AAV actually is and why it is relevant. For those of us who lack basic biotech knowledge, it can be useful to have things explained at an amateur level. I have no intention of filling the feed with AI content, but I thought this one might be interesting for several people. It was generated by Claude and I think it's worth sharing. What is AAV? AAV stands for adeno-associated virus. It is a small virus that occurs naturally in humans – most of us have had it without noticing anything at all. It doesn't make anyone sick and is therefore ideal as a transport vehicle for medicine. Researchers have practically emptied the virus of all genetic content and use the empty shell – called a capsid – as a biological package. Inside the package, they place a therapeutic gene, i.e., a corrected version of a gene that is defective in the patient. Think of it as a letter. AAV is the envelope. The gene is the letter inside. The cell is the recipient that opens the envelope and reads the instructions. What happens inside the cell? When AAV delivers the gene into the cell, the cell begins to read the instructions and produce the protein the gene codes for. If, for example, the patient lacks a specific protein that keeps the heart healthy, AAV can deliver the instruction that causes the heart to produce this protein itself. That is why AAV gene therapy is revolutionary – in theory, hereditary diseases can be cured with a single treatment. Problem 1 – Can only be used once: The body is smart. After the first time it sees the envelope – i.e., the AAV capsid – it produces antibodies against it. The next time you try to send a new letter in the same envelope, the immune system immediately attacks it before it arrives. You cannot re-dose the patient with the same AAV type. This is a critical problem because many diseases require sustained treatment over time, not just a single dose. Problem 2 – High doses and toxicity: For enough letters to reach the correct cells, an extremely large number of envelopes must be sent at once. Imagine sending a million letters for 10,000 to reach the correct address. The problem is that so many envelopes at once overwhelm the immune system. The body interprets it as a massive attack and reacts with strong inflammation – in the worst case, acute immune shock which can be fatal. Several patients have actually died in clinical studies because of this. Problem 3 – Liver off-targeting: AAV tends to end up in the liver regardless of where in the body it is actually addressed. If the letter is intended for the heart or the eye, many envelopes still end up in the liver – where they are not needed and can potentially cause damage. Problem 4 – Short duration: Even when the letter arrives and the cell reads the instructions, the effect is limited in time. Cells divide and dilute the content, and the protein produced decreases over time. One might get a few months to a few years of effect, but rarely lifelong treatment from a single dose.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
39 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenCircio has a management with an unusually strong combination of circRNA expertise, pharma experience and transactional understanding. The management and primary insiders also have significant exposure through shares, options and warrants, and thus have economic alignment with the shareholders.
- ·3 t sittenWhen should one enter Circio again at the latest? When are important days?·55 min sittenAt the latest one day before a stock exchange announcement about an acquisition…. Your question is impossible to answer, especially if we don't know if you are a trader or are long in Circio. But right now, you at least have a golden opportunity to secure an option to buy the share at a specific price if you are considering entering now: If you buy warrants (last price Friday:kr 0.45) then you can, until June 9th, consider whether you wish to buy the share for kr 8.2508 REGARDLESS of what price the Circio share has. And should the price fall below kr 8.2508, you simply buy the share without exercising the warrants. Be aware that the price of warrants often rises more sharply than the share price now that the VWAP period is over.
- ·7 t sittenI have read a lot about Circio and circRNA, but have never fully understood what AAV actually is and why it is relevant. For those of us who lack basic biotech knowledge, it can be useful to have things explained at an amateur level. I have no intention of filling the feed with AI content, but I thought this one might be interesting for several people. It was generated by Claude and I think it's worth sharing. What is AAV? AAV stands for adeno-associated virus. It is a small virus that occurs naturally in humans – most of us have had it without noticing anything at all. It doesn't make anyone sick and is therefore ideal as a transport vehicle for medicine. Researchers have practically emptied the virus of all genetic content and use the empty shell – called a capsid – as a biological package. Inside the package, they place a therapeutic gene, i.e., a corrected version of a gene that is defective in the patient. Think of it as a letter. AAV is the envelope. The gene is the letter inside. The cell is the recipient that opens the envelope and reads the instructions. What happens inside the cell? When AAV delivers the gene into the cell, the cell begins to read the instructions and produce the protein the gene codes for. If, for example, the patient lacks a specific protein that keeps the heart healthy, AAV can deliver the instruction that causes the heart to produce this protein itself. That is why AAV gene therapy is revolutionary – in theory, hereditary diseases can be cured with a single treatment. Problem 1 – Can only be used once: The body is smart. After the first time it sees the envelope – i.e., the AAV capsid – it produces antibodies against it. The next time you try to send a new letter in the same envelope, the immune system immediately attacks it before it arrives. You cannot re-dose the patient with the same AAV type. This is a critical problem because many diseases require sustained treatment over time, not just a single dose. Problem 2 – High doses and toxicity: For enough letters to reach the correct cells, an extremely large number of envelopes must be sent at once. Imagine sending a million letters for 10,000 to reach the correct address. The problem is that so many envelopes at once overwhelm the immune system. The body interprets it as a massive attack and reacts with strong inflammation – in the worst case, acute immune shock which can be fatal. Several patients have actually died in clinical studies because of this. Problem 3 – Liver off-targeting: AAV tends to end up in the liver regardless of where in the body it is actually addressed. If the letter is intended for the heart or the eye, many envelopes still end up in the liver – where they are not needed and can potentially cause damage. Problem 4 – Short duration: Even when the letter arrives and the cell reads the instructions, the effect is limited in time. Cells divide and dilute the content, and the protein produced decreases over time. One might get a few months to a few years of effect, but rarely lifelong treatment from a single dose.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 953 | - | - | ||
| 7 618 | - | - | ||
| 784 | - | - | ||
| 357 | - | - | ||
| 33 323 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt